Modified-release hydrocortisone to provide circadian cortisol profiles by Debono, M. et al.
promoting access to White Rose research papers 
   










This is an author produced version of a paper published in Journal of Clinical 
Endocrinology and Metabolism.  
 
 
White Rose Research Online URL for this paper: 





Debono M, Ghobadi C, Rostami-Hodjegan A, Ross RJ et al. (2009) Modified-Release 
Hydrocortisone to Provide Circadian Cortisol Profiles, Journal of Clinical 
Endocrinology and Metabolism, 94(5) pp.1548-1554  
http://dx.doi.org/10.1210/jc.2008-2380   
 
 1
Modified-release hydrocortisone to provide circadian cortisol profiles  
 
Short title: Circadian hydrocortisone therapy 
 
Authors: Miguel Debono1, Cyrus Ghobadi2, Amin Rostami-Hodjegan2, Hiep Huatan3, Michael J 
Campbell4, John Newell-Price1, Ken Darzy5, Deborah P Merke6, Wiebke Arlt7 and Richard J 
Ross1. 
 
Affiliations: 1Academic Unit of Diabetes, Endocrinology & Metabolism & 2Academic Unit of 
Clinical Pharmacology, School of Medicine, Royal Hallamshire Hospital, University of Sheffield, 
Sheffield, UK; 3H2Pharma; 4Health Services Research ScHARR, University of Sheffield, Regent 
Court, 30 Regent street, Sheffield, UK; 5Diabetes and Endocrinology, East and North 
Hertfordshire NHS Trust, Howlands, Welwyn Garden City, UK; 6National Institutes of Health 
Clinical Center and The Eunice Kennedy Shriver National Institute of Child Health and Human 
Development, Bethesda, MD, USA; 7Section Endocrinology, Diabetes & Metabolism, School of 
Clinical & Experimental Medicine, University of Birmingham, Birmingham, UK  
 
Corresponding author: Professor Richard JM Ross, University of Sheffield, Room 112 Floor 




MD, CG, MC, JN-P, KD, WA have nothing to declare. DPM received research funds from 
Phoqus Plc. RR & AR have equity interests in (Diurnal Ltd). HH is employed as a consultant for 
Diurnal Ltd.  
 
This is an un-copyedited author manuscript copyrighted by The Endocrine Society. This may not 
be duplicated or reproduced, other that for personal use or within the rule of “Fair Use of 
Copyrighted Materials” (section 107, Title 17, U.S. Code) without permission of the copyright 
owner, The Endocrine Society. From the time of acceptance following peer review, the full text 
of this manuscript is made freely available by The Endocrine Society at 
http://www.endojournals.org/. The final copy edited article can be found at 
http://www.endojournals.org/. The Endocrine Society disclaims any responsibility or liability for 
 2
errors or omissions in this version of the manuscript or in any version derived from it by the 
National Institutes of Health or other parties. The citation of this article must include the 
following information: author(s), article title, journal title, year of publication, and DOI. 
 
Word Count: 2755 (main text), 250 (abstract), 4 Tables; 3 Figures 
Key Terms: hydrocortisone, modified-release, adrenal insufficiency, circadian  
Precis: A modified release formulation of hydrocortisone that allows for delayed and sustained 























Context: Cortisol has a distinct circadian rhythm regulated by the brain’s central pacemaker. 
Loss of this rhythm is associated with metabolic abnormalities, fatigue and poor quality of life. 
Conventional glucocorticoid replacement cannot replicate this rhythm.  
Objectives: To define key variables of physiological cortisol rhythm and by pharmacokinetic 
modelling test whether modified-release hydrocortisone (MR-HC) can provide circadian cortisol 
profiles. 
Setting: Clinical Research Facility.   
Design and Methods: Using data from a cross-sectional study in healthy reference subjects 
(n=33) we defined parameters for the cortisol rhythm. We then tested MR-HC against immediate-
release (IR-HC) in healthy volunteers (n=28) in an open-label, randomised, single-dose, 
crossover study. We compared profiles to physiological cortisol levels, and modelled an optimal 
treatment regimen. 
Results: The key variables in the physiological cortisol profile included: peak 15.5mcg/dL (95% 
reference range 11.7–20.6), acrophase 0832h (95%CI 0759h–0905h), nadir<2mcg/dL (95% 
reference range 1.5-2.5), time of nadir 0018h (95%CI 2339h–0058h), and quiescent phase (below 
the mesor) 1943h to 0531h. MR-HC 15mg demonstrated delayed and sustained release with a 
mean (SEM) Cmax of 16.6 (1.4) mcg/dL at 7·41 (0·57) hrs after drug. Bioavailability of MR-HC 5, 
10 & 15mg was 100, 79, & 86% that of IR-HC. Modelling suggested that MR-HC 15 to 20mg at 
2300h and 10mg at 0700h could reproduce physiological cortisol levels. 
Conclusion: By defining circadian rhythms and using modern formulation technology it is 






Cortisol secretion follows a distinct circadian rhythm, with circulating levels low at sleep onset, 
beginning to rise between 0200h and 0400h, peaking within an hour of waking and then declining 
through the day (1). This circadian rhythm is determined by the central endogenous clock 
(pacemaker) of the hypothalamic-pituitary-adrenal (HPA) axis, located in the hypothalamic 
supra-chiasmatic nucleus (SCN), which drives release of corticotropin releasing hormone (CRH), 
in turn leading to secretion of adrenocorticotropin (ACTH) from the pituitary and thus cortisol 
from the adrenal.  
 
The central SCN clock has an approximate period length of 24·2 hours, and requires daily 
adjustment by photoperiod to synchronize to the 24 hour day/night cycle. In addition to the 
central clock, there are molecular oscillators (peripheral clocks) in most mammalian cells (2). The 
phase of these peripheral clocks is reset by signals from the central pacemaker. The specific 
signals from the central to peripheral clocks have not been fully established. Circadian gene 
expression can be induced by serum shock (3), and glucocorticoids are able to phase delay or 
advance peripheral oscillators (4).  Thus cortisol appears to act as one secondary messenger from 
central to peripheral clocks. 
 
The HPA axis plays an important role in maintaining alertness and modulating sleep (5). 
Conditions associated with insomnia including depression, sleep apnoea, and chronic fatigue, 
disrupt the circadian rhythm of cortisol leading to metabolic abnormalities and increased 
cardiovascular risk (6, 7). Patients with adrenal insufficiency have loss of the normal circadian 
rhythm of cortisol and excess mortality mainly from cardiovascular events and infections (8-10). 
This may be explained in part by the fact that current replacement regimens cannot replace the 
normal physiological rhythm of cortisol (11). Moreover, with current replacement regimes the 
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majority of patients with adrenal insufficiency report impaired health-related quality of life (HR-
QOL) (12, 13), and early morning fatigue (14, 15) with subsequent socioeconomic health 
problems. Hence, physiological cortisol replacement in patients with adrenal insufficiency may 
be advantageous when compared to conventional treatments. 
 
Infusions of hydrocortisone (cortisol) can mimic the normal circadian rhythm of cortisol and 
improve biochemical control and quality of life in patients with adrenal insufficiency (16, 17). 
Since infusions are not a practical solution, we designed a modified release hydrocortisone (MR-
HC). A small proof of concept study confirmed the potential utility of the formulation to 
reproduce the normal overnight rise in cortisol levels (18).  
 
We have now analyzed circadian cortisol levels from a group of healthy subjects to define the 
parameters of physiological cortisol secretion. These can then be used to judge any new therapy 
that aims for physiological circadian replacement of cortisol. We have then performed a detailed 
phase 1 study on new modified-release formulations of hydrocortisone (MR-HC) and compared 
them to the kinetics of 10mg immediate-release hydrocortisone (IR-HC), the conventional 
hydrocortisone preparation currently used in routine clinical care for adrenal insufficiency and 
congenital adrenal hyperplasia. These data were then used to define optimal treatment regimens 
with MR-HC for mimicking physiological cortisol levels, a novel concept in the delivery of 
glucocorticoid replacement. 
 
Subjects and Methods 
Healthy reference group 
33 normal individuals who had undergone detailed, 24-hour, 20-minute, cortisol profiling 
provided data for definition of the physiological cortisol circadian rhythm (Table 1) (19). This 
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data set was used as all individual measurements were available to us and the data was generated 
with the same modern cortisol assay. To further validate that this data set is representative of the 
general population all mean (±95% confidence intervals (CI)) cortisol concentrations, AUC(0-24)  
and time variables obtained from the healthy reference group were compared to similar variables 
derived from the previously published literature (20-29).  
 
Defining physiological ranges 
Cortisol levels generally show a skewed distribution. Therefore, in defining physiological ranges 
cortisol levels were transformed to the natural logarithm enabling the cortisol geometric mean to 
be calculated at each time point. 95% CI were calculated for: the AUC(0-24) (area under the curve 
from time 0 to 24 hours), peak cortisol, trough cortisol and 24-hour mean cortisol. In addition we 
report 95% reference ranges (±2SD) for the peak and trough cortisol.  
 
Cosinor analysis 
For each individual cortisol profile, a cosinor model with a second harmonic was fitted to the data 
(30). A group cosinor model was computed by averaging the coefficients from the individual fits. 
Circadian timing estimates were obtained for each individual cortisol profile. This allowed us to 
calculate the mesor (rhythm adjusted mean), the acrophase (time of peak in rhythm), the nadir 
(lowest point of the rhythm), and the quiescent phase (start, taken as the time when the cortisol 
level was equal or less to the mesor for more than an hour, and end, when the cortisol level was 
equal or more to the mesor for more than an hour). In a previous study reporting the quiescent 
phase, the cutoff for the start and end was taken as 5 mcg/dL (138nmol/l) (21), a very similar 
value to the mesor 5.2 mcg/dL (143·6nmol/l) that we obtained for use in this study. 
 
Pharmacokinetic Analysis for modified-release hydrocortisone 
32 healthy male subjects were recruited. Entry criteria: 18 to 50 years; no illness, operation or 
steroid use in the previous three months and no regular medication. The study was approved by 
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the Plymouth Independent Ethics Committee, UK and all subjects gave informed written consent. 
The sampling was performed in the Chiltern Clinical Research Unit, UK.  
 
Dose-response study 
20 subjects were randomized to receive three of the following four single-dose regimes: 5mg 
MR-HC (1x5mg), 15mg MR-HC (1x15mg), 30mg MR-HC (2x15mg), 10mg immediate release 
hydrocortisone (IR-HC) with a one week washout between treatments. 12 other subjects were 
randomized to receive either 10mg (2x5mg) of MR-HC or 10mg IR-HC with a one-week washout 
period.  
 
The MR-HC or IR-HC dose was taken at 2200h. Participants had their HPA axis suppressed with 
1mg oral dexamethasone at 1800h and 2200h on Day 1 and then at 0600h,  1200h and 1800h on 
Day 2 during each treatment period. Plasma ACTH levels were taken at 2155h on Day 1 and on 
0600h on Day 2 whilst serum cortisol levels were taken prior to ingestion of the drug and were 
repeated every 30 minutes for the first four hours, then at 0200h, 0300h, 0400h, 0500h, 0600h, 
0800h, 1000h, 1300h, 1600h, 2200h (Table 2).   
 
MR-HC 
The tablet has an insoluble barrier coat protecting all but the upper face of the tablet. The 
unprotected face exposes a delaying layer that slowly erodes in the small intestine to present the 
sustained release drug-containing layer. Two different dose units of MR-HC were available, 5mg 
and 15mg.  MR-HC was supplied by Phoqus PLC (Kent, UK). 
 
IR-HC 
10mg tablets were from MSD (Hertfordshire, UK). A 10mg dose was used to avoid un-
physiological peak values that exceed the binding capacity of cortisol binding globulin which in 
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our view would complicate the analysis when comparing PK values to a modified release 
formulation of hydrocortisone (31). 
 
Assays 
Serum cortisol was measured using the Bayer Advia Centaur Automated Immunoassay System. 
The inter-assay coefficient variation was 7% at 7·2μg/dl (200nmol/l), and 8% at 38μg/dl 
(1,050nmol/l). Plasma ACTH was measured using the DPC Immulite 2000 assay. The inter-assay 
coefficient variation was 4% at 28ng/l (6·2pmol/l). The same assay methodology was used in the 
healthy reference group.   
 
Statistical Analysis 
Pharmacokinetic (PK) parameters were computed by non-compartmental analysis. As only a 
10mg dose of IR-HC was used, to assess relative bioavailability MR-HC was dose adjusted as 
follows: (AUC(MR-HC)×Dose(IR-HC)/(AUC(IR-HC)×Dose(MR-HC). Independent sample T- 
test was used to compare PK data of MR-HC and IR-HC. A significant difference was taken as p 
<0.05. Dose proportionality was determined by comparing AUC(0-inf), and Cmax of the 5mg, 15mg 
and 30mg MR-HC doses using a linear model approach on the log-transformed pharmacokinetic 
parameters versus log-transformed doses. The slope of the response against dose estimated, and 
dose proportionality accepted if the 90% confidence interval for the slope included unity.  
 
In modeling we simulated giving MR-HC doses at different times and once or twice daily to 
establish whether MR-HC could produce a 24-hour physiological profile. To examine the best fit 
we calculated the ratio between the MR-HC AUC versus the physiological AUC at each of the 
pharmacokinetically relevant time intervals, e.g. the trapezoidal segment between each sampling 
interval. A ratio between 0·8 and 1·2 (within 20% of identity) was considered to indicate an 
acceptable MR-HC fit for that time interval. We could then determine the proportion of cortisol 
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levels after MR-HC that fell between the upper and lower 95% reference ranges for physiological 
cortisol levels.  
 
Results 
Defining the Physiological Cortisol Circadian Rhythm 
A circadian rhythm is clearly demonstrated in the data from the healthy reference group 
(Figure1). A cosinor model with second harmonic gave an excellent fit to the mean cortisol data 
(r2=0·97, p<0·001). All individuals had a significant (P<0.001) sinusoidal rhythm. Cortisol levels 
reached a peak at around 0832h (95%CI 0759h–0905h), then levels gradually decreased until 
reaching a nadir at 0018h (95%CI 2339 – 0058h). Two smaller peaks occurred at meal times.  
The means for all variables of the healthy reference group were similar to the previously 
published literature with overlap of all 95% CIs (Table 1) (20-29). In this cohort there was no 
difference in the level or phase of the circadian rhythm between men and women.  
 
Pharmacokinetic Analysis of MR-HC and Comparison to IR-HC 
Thirty two subjects were recruited. Four participants were withdrawn; two for violation of the 
protocol, one withdrew consent and one had an adverse event whilst on IR-HC (hiccups). The 
twenty eight other subjects completed the study (Table 3). 98% of all ACTH values were below 
the lower limit of the assay confirming dexamethasone-induced suppression of endogenous HPA 
axis, a mandatory precondition for correct pharmacokinetic analysis of cortisol bioavailability. 
 
The cortisol concentration-time profiles following administration of MR-HC and IR-HC are 
shown in Figure 2. The summary statistics for the pharmacokinetic parameters is represented in 
Table 4 for comparison.  The meangeo (90%CI) relative bioavailability of MR-HC formulations 
compared to that of IR-HC, as measured by dose-normalized AUC values, were: 100% (90-
112%) for 5mg, 79% (66-95%) for 10mg, 86% (77-96%) for 15mg, and 69% (62-77%) for 30mg, 
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respectively. The corresponding analysis for the maximum exposure, as measured by Cmax 
(without dose–normalization), indicated equivalence of the MR-HC 15mg dose to IR-HC 10mg 
[92% (77% - 107%)]. As expected from a delayed and sustained release formulation, the MR-HC 
15mg dose showed a marked delay in mean Tmax, prolongation in Tlag, and lower dose-normalized 
Cmax compared to IR-HC 10mg dose [Tmax (95% CI): (7.41 (6.16 - 8.66) hrs vs 1.8 (1.4 – 2.2) hrs,  
p≤0.001); Tlag (5.19 (4.3 – 6.09) hrs vs 0.5 (0.33 vs 0.67) hrs, p<0.001; dose-adjusted Cmax  (11.04 
(9.02 – 13.06) mcg/dL vs 18.4 (16.9 – 19.9) mcg/dL, p≤0.001). All other formulations also 
showed characteristics of sustained and delayed release (Table 4). The peak concentrations and 
cortisol exposure increased predictably with increasing MR-HC dose. Dose proportionality was 
seen for MR-HC 5mg and 15mg: slope (90% CIs) were 0·82 (0·62-1·02) and 0·9 (0·69-1·1) for 
AUC(0-inf) and Cmax, respectively.  Dose proportionality was not shown between 15 mg and 30 mg 
MR-HC formulation: slopes (90%CI) for AUC(0-inf), and Cmax were,  0·58 (0·30-0·85) and 0·64 
(0·40-0·87), respectively. There was no correlation between weight and any variable of MR-HC 
pharmacokinetics. 
 
Comparison of MR-HC to the Physiological Cortisol Profile  
Administration of 30mg MR-HC provided the best cortisol exposure over 24 hours based on 
AUC compared to the physiological profile: mean (90%CI) = 88% (77–99%). However, the 
30mg MR-HC Cmax was above that seen for the physiological peak (mean±SEM = 24.9±1.1 vs 
15.5±0.8 mcg/dL) and the peak occurred earlier than the physiological peak (mean: 0600h vs 
0832h). The cortisol profile following MR-HC suggests that it only provides approximately 12 
hours exposure to hydrocortisone (Figure 2) and when looking at the AUC for 12 hours after 
2200h for 15mg MR-HC cortisol exposure was 84% (71–97%) of physiological, the Cmax similar 
to physiological peak (16.6±1.4 vs 15.5±0.8 mcg/dL) but occurred earlier (0600h vs 0832h) when 
given at 2200h.  
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Modeling MR-HC Data to Provide Physiological Dosing Regimen 
Based on the phase 1 MR-HC data obtained from the dose-response study using single 
dose regimes, we simulated giving MR-HC doses at different times and once or twice 
daily. For MR-HC 30mg given at 2200h, only 2 cortisol AUCs of the 16 (12.5%) fell within the 
0.8 to 1.2 ratio. However, 12 (75%) of 16 cortisol AUCs fell within the 0.8 to 1.2 ratio for MR-
HC given as 20mg at 2300h and 10mg at 0700 . Using this analysis we defined the best dose 
combination to provide physiological cortisol levels as either 15 or 20mg MR-HC at 2300h and 
10mg MR-HC at 0700h. An example profile is shown in Figure 3 against physiological cortisol 
levels.   
 
Discussion 
Physiological cortisol replacement therapy for adrenal insufficiency is not possible with current 
oral hydrocortisone formulations (32). To address this we have developed a novel modified-
release formulation of hydrocortisone (MR-HC). We have undertaken detailed pharmacokinetics 
of MR-HC and compared these with the physiological profile of cortisol in normal individuals. 
Based on pharmacokinetic modelling we suggest that a twice daily regimen of MR-HC given at 
2300 and 0700h can provide levels of cortisol similar to normal physiological cortisol; AUC, Cmax 
and Tmax.  
 
Defining the normal physiological profile of cortisol was critical to our study. We had access to a 
dataset of 33 healthy individuals who had undergone 20 minute blood sampling over a 24 hour 
period (19). The generalisability of these data is reflected by the fact that the peak and nadir 
cortisol, the timing of the peak and nadir, the duration of the quiescent phase and the onset of 
cortisol secretion and cosinor analysis were all very similar to that in the literature (20-29). The 
key variables in the cortisol profile that were defined were a peak cortisol of 15.5 mcg/dL (95% 
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reference range 11.7 – 20.6), with the acrophase at 0832h (95%CI 0759h – 0905h), a nadir 
cortisol of <2 mcg/dL (95% reference range 1.5 – 2.5) occurring at 0018h (95%CI 2339h – 
0058h) and the quiescent phase (below the mesor) occurring from 1943h to 0531h.  
 
We found no difference in physiological cortisol profiles according to weight or gender. Gender 
has previously been reported to have a minor effect on physiological cortisol levels (21) although 
not found in all studies (33). BMI does not have any significant effect on parameters quantifying 
the 24-hour cortisol profile in lean or modestly overweight individuals (21). In the literature there 
is an age effect on the cortisol profile and older subjects have an earlier onset of the cortisol 
rhythm (22). Most of our subjects were young and Caucasian. However, different populations and 
ethnic groups may exhibit differences in circadian cortisol rhythm parameters. For example, 
trough and peak cortisol levels occur earlier in Chinese men compared to Caucasians, possibly 
due to genetic differences and or environmental influences including social activity and everyday 
habits on entrainment of circadian rhythms, such as  an average earlier bedtime (26).  
 
The pharmacokinetics of MR-HC showed similar bioavailability to IR-HC with dose-
proportionality for MR-HC between 5 and 15mg but not between 15 and 30mg.  This is likely to 
be explained by the binding characteristics of CBG.  Under basal conditions about 5% to 10% of 
circulating cortisol is free, about 75% is bound to CBG, and the remainder is bound to albumin. 
Increases in total plasma cortisol concentrations above 20 mcg/dL (550nmol/L) exceed the 
binding capacity of CBG and result in rapid increases in levels of free cortisol concentration, 
which thus exhibits more rapid clearance from the circulation (31). As the peak cortisol following 
30mg MR-HC exceeded 20 mcg/dL, the lack of dose-proportionality is probably explained by 
this mechanism.  
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The profile following MR-HC was compared to physiological cortisol levels. The 
pharmacokinetic studies were all undertaken with subjects taking a single dose at 2200h. Based 
on this the onset of cortisol release preceded the end of the physiological quiescent phase and the 
peak preceded the timing of physiological peak cortisol. In addition a single dose of MR-HC 
could only replace the 24 hour AUC if the peak cortisol exceeded the physiological peak. We 
simulated, therefore, giving MR-HC at different time points and once or twice daily. In the 
simulations AUC at time intervals were compared with the normal circadian rhythm. This 
analysis shows that MR-HC 20mg and 10mg, given at 2300 and 0700h, respectively, could 
provide a cortisol profile with the least difference from normal physiological cortisol levels. 
However, this conclusion requires validation by an appropriate clinical study and it should be 
recognised that all simulations have been done on data derived from adults and a different 
regimen both in timing and dose will be required for children 
 
The future of endocrine replacement lies in using modern pharmaceutical formulations to provide 
hormone replacement that replicates physiological hormone levels. We recognise that it is 
unlikely that any future drug regimen will be able to completely replicate the rapid adaptation of 
physiological cortisol secretion to different conditions of stress. However, we have shown that a 
modified release formulation of hydrocortisone that allows for delayed and sustained release of 
hydrocortisone can potentially replicate normal un-stressed physiological cortisol levels. 
Currently, in patients with adrenal insufficiency, health-related quality of life is significantly 
compromised, affecting their ability to work and cope with activities of daily life, and even more 
significant, mortality is increased. Future studies will determine the beneficial effects of 
physiological cortisol replacement but we have demonstrated here that it is possible to generate 
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Table 1: Characteristics of Cortisol Circadian Rhythm – Comparison of 
Mean (±95% Confidence Intervals) Cortisol Concentrations, AUC 
and Time Variables in our healthy reference group (Darzy 2005) 
to similar variables in previously published data.   
   
Author Sample 
Mean Age 


























(24 Males;  
9 Females) 
 
    27  
(17-57) 



































 38 Females) 
 






























        
 
1 Variable Mean (95% Confidence Intervals) 
2 Values have been estimated from published data: Mean (Range) 
b1 Period starts  when Cortisol level ~ 5.2 mcg/dL or less for at least 1h 
b2 Period starts  when Cortisol level ~ 5.0 mcg/dL or less for at least 1h  
c1 Period starts when Cortisol levels ~ 5.2 mcg/dL or more for at least 1h 
c2 Period starts when Cortisol levels ~ 5.0 mcg/dL or more for at least 1h 
 
Notes: 
- Sample – subgroups used in analysis: (21) 20-29 yr subgroup, (22)19-25 yr subgroup, (24) S1 session, 
(25) Control group, (26) Chinese, 30 yr sub group  
- AUC: Ref (23) - curve represents average of harmonic regressions  
- Not used in analysis of:  Trough: Ref (22); 24-hour mean cortisol: Ref (22, 28); Time of Nadir: Ref (26, 











Table 2: Study Scheme: Subjects admitted to Clinical Research Facility 
on day 1. Subjects tested on up to 3 occasions with a one week washout 





          
DAY 2 
        
         STUDY ASSESSMENT 




    
    ¸ 
    
    ¸ 
   
 
DEXAMETHASONE 1MG ORALLY 
 
  
  ¸ 
    
    ¸ 
    
    ¸ 
    
    ¸ 
   
    ¸ 
 
 
20* SUBJECTS DOSED WITH MR-HC 5MG, 
15MG, 30MG OR IR-HC 10MG 
 
12 SUBJECTS DOSED WITH MR-HC 10MG 





    
 
    ¸ 
    
       
        
CORTISOL MEASUREMENT 
  
Predose, postdose sampling every 30 
minutes for the first 4 hours then at 5, 6,  
7, 8, 10, 12, 15, 18 and 24 hours post dose 
 
 


























         Group 
  Main Study  
     Group    
      
 
Number of Subjects 
         
               33 
  
          28 
 
Sex 
   
  24 Males / 9 Females 
       
   28 Males 
 
Mean Age  
  (range) 
               
             27   
       (17 - 57) 
      
  33      
  (21 - 46) 
 
Mean Weight  
  (range) 
               
            67.1 
       (54 - 102)   
        
  80·0 
  (58 - 103)  
 
Mean BMI 
  (range) 
               
            22·9 
       (17 -  29)                 
     
   25·6  






























    MR-HC  
      5mg 
(12 subjects) 
    MR-HC  
    10mg 
(12 subjects) 
    MR-HC 
     15mg 
(12 subjects) 
    MR-HC  
     30mg 
(12 subjects) 
    10mg IR  
Hydro- 
cortisone 











































































































AUC(0-24)   Area under the plasma concentration-time curve for 24 hours  
AUC(0-inf)   Area under the plasma concentration-time curve extrapolated to infinity 
Cmax   Maximum observed concentration 
Tmax   Time to reach Cmax  
Tlag     Time delay between drug administration and cortisol concentration > 3.5 mcg/dL  









Figure Legends  
Figure 1: Physiological Cortisol Circadian Rhythm: The figure shows the geometric mean 
(▬) plus/minus 2SD (▬) serum cortisol concentration calculated from 20-minute sampling over 
a 24-hour period in 33 healthy subjects. The fitted cosinor (▬) is the average of harmonic 
regressions that were a fit for the individual subject data. Cortisol has a distinct circadian rhythm 
with a peak of 15.5 mcg/dL (95% reference range 11.7 – 20.6) occurring at 0832h and a nadir < 
2.0 mcg/dL (95% reference range 1.5 – 2.5) at 0018h. Mesor = Midline estimating statistic of 
rhythm. Acrophase = Time of peak using a 24-hour clock with midnight taken as origin. Nadir = 
Time of trough cortisol level. The mean and 95%CI are shown for the mesor, acrophase and 
nadir. 
 
Figure 2: Concentration – time profiles for MR-HC and IR-HC: Concentration – time 
profiles for different doses of MR-HC given at 2200h compared to 10mg IR-HC using geometric 
means (±SEM) of serum cortisol concentrations at 18 different time points over 24 hours.  
Profiles of MR-HC show a prolonged Tmax, Tlag, and a lower dose-adjusted Cmax (not shown) 
when compared to IR-HC, all typical of a formulation with delayed and sustained release 
characteristics.  
 
Figure 3: Simulation of Physiological Cortisol rhythm using MR-HC: Phase 1 PK data were 
used to simulate giving MR-HC doses at different times and once or twice daily. PK modelling 
included comparison of MR-HC to the physiological cortisol rhythm over 12 and 24 hours, and at 
different time intervals (trapezoidal segments), using AUCs. The graph shows modeled 
concentration-time profile (▬) obtained when giving 20mg (15mg + 5mg) MR-HC at 2300h and 
10mg MR-HC at 0700h superimposed on the physiological cortisol rhythm (geometric mean (▬) 
± 2SD (▬) serum cortisol concentration calculated from 20-minute sampling over a 24-hour 
period in 33 healthy subjects).  
